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Background: Over the last decade two alternative models of donor care have emerged in the United 
States: the conventional model, whereby donors are managed at the hospital where brain death occurs, and 
the specialized donor care facility (SDCF), in which brain dead donors are transferred to a SDCF for medical 
optimization and organ procurement. Despite increasing use of the SDCF model, its cost-effectiveness in 
comparison to the conventional model remains unknown.
Methods: We performed an economic evaluation of the SDCF and conventional model of donor care from 
the perspective of U.S. transplant centers over a 2-year study period. In this analysis, we utilized nationwide 
data from the Scientific Registry of Transplant Recipients and controlled for donor characteristics and 
patterns of organ sharing across the nation’s organ procurement organizations (OPOs). Subgroup analysis 
was performed to determine the impact of the SDCF model on thoracic organ transplants.
Results: A total of 38,944 organ transplants were performed in the U.S. during the study period from 
13,539 donors with an observed total organ cost of $1.36 billion. If every OPO assumed the cost and 
effectiveness of the SDCF model, a predicted 39,155 organ transplants (+211) would have been performed 
with a predicted total organ cost of $1.26 billion (−$100 million). Subgroup analysis of thoracic organs 
revealed that the SDCF model would lead to a predicted 156 additional transplants with a cost saving of  
$24.6 million.
Conclusions: The U.S. SDCF model may be a less costly and more effective means of multi-organ donor 
management, particularly for thoracic organ donors, compared to the conventional hospital-based model.
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Introduction
The number of deceased organ donors and solid organ 
transplants in the United States (U.S.) has consistently risen 
in recent years, with approximately 36,500 transplants from 
10,700 deceased donors performed in 2018 alone (1). The 
current method of organ allocation allows donors to be 
matched with appropriate recipients nationwide, requiring 
substantial coordination and typically necessitating travel 
by several transplant teams for each donor (2). Donor 
management, organ allocation, and procurement operations 
are coordinated by 58 federally mandated, non-profit organ 
procurement organizations (OPOs), each managing donors 
within its respective geographic service area. Traditionally, 
this requires a donor’s OPO to communicate extensively 
with multiple transplant centers and coordinate care with 
the referring hospital where the donor resides. In an effort 
to optimize the efficiency of this process and potentially 
reduce costs, our local OPO, Mid-America Transplant 
(MOMA), built the country’s first freestanding specialized 
donor care facility (SDCF) in 2001. In this model, donation 
after brain death donors are transferred from the referring 
hospital to the SDCF for medical optimization while 
organ allocation is coordinated with transplant centers 
(Figure 1). The SDCF maintains its own in-house critical 
care unit, laboratory, radiographic equipment (i.e., CT 
scanner), and procurement operating rooms, resulting in a 
streamlined process of donor care. After the donor workup 
is complete and organs have been accepted by transplant 
centers, procurement teams travel to the SDCF for organ 
procurement.
By 2011, 93% of all procurements from MOMA were 
being conducted at the SDCF, which was associated with 
a reduction in surgeon air travel and overall cost of donor 
management (3,4). Furthermore, organ procurement from 
MOMA’s SDCF has been associated with an increase in 
organ yield per donor (4,5). At least 12 other OPOs in the 
U.S. have since either adopted the SDCF model or are in 
the process of doing so. However, a national comparison 
of the SDCF model with the conventional model of donor 
management while controlling for donor characteristics 
has not been performed. Furthermore, a nationwide 
economic evaluation from the perspective of U.S. transplant 
centers has also not been previously conducted. This holds 
tremendous importance with regards to donor management 
policy given the limited resources and wide variability of 
donor characteristics and organ acquisition costs. Not 
only is this important for transplant centers in the U.S., 
it is likely that the SDCF model of care has important 
characteristics that can be successfully adapted to support 
organ transplantation, particularly for thoracic organs, 
worldwide.
Given the sustained increase in organ donors over 
the last decade and the high cost associated with organ 
acquisition, it is critically important to compare the various 
models of donor care. To address this gap, we conducted 
an economic evaluation of the SDCF model compared to 
the conventional model of donor care in the U.S. from the 
perspective of transplant centers. We present the following 
article in accordance with the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) 
reporting checklist (available at http://dx.doi.org/10.21037/
jtd-20-1575).
Methods
In this analysis we conducted an economic evaluation from 
a transplant center’s perspective to compare the SDCF 
model with the conventional model of hospital-based donor 
care. To accomplish this, we compare the observed (actual) 
cost and effectiveness of the nation’s OPOs during the 
study period with that of a predicted scenario in which all 
OPOs adopted the SDCF model of care. We chose to use 
nationwide data from the Scientific Registry of Transplant 
Recipients (SRTR) (6) to measure effectiveness, as this data 
is rigorously adjusted for individual donor characteristics 
and allows for accurate comparisons of performance among 
our country’s OPOs. We adjusted for patterns of organ 
sharing across the nation’s OPOs which vary across different 
regions of the country.
Organ acquisition charge (OAC) was used to compute 
organ costs. When a transplant center (e.g., Barnes-Jewish 
Hospital) accepts an organ for transplantation, the OAC is 
paid by that center to the respective OPO (e.g., MOMA) 
and ultimately reimbursed by private insurance companies 
or the government via the Center for Medicare & Medicaid 
Services. The OAC is used by OPOs to fund the cost of 
managing an organ donor in the hospital, coordinating 
the donation process, reimbursing hospitals for operating 
room charges, and in the case of an SDCF, transportation 
and management of the donor at the facility. Therefore, the 
OAC of an organ represents the unit cost of that organ to 
a transplant center. At MOMA, the OAC for a given organ 
does not change based on donation after brain death or 
cardiac death status.
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Cost savings in the absence of comparable or improved 
effectiveness would be undesirable in any new model of 
care. Therefore, effectiveness was measured using each 
OPO’s observed and predicted number of transplants 
performed during the study period for heart, lung, liver, 
kidney, and pancreas. Single and double lung transplants 
were counted as one organ, while kidney transplants were 
counted separately. Due to their rarity, small intestine 
transplants were excluded from the analyses (Figure S1). 
Both donation after cardiac death and brain-dead donors 
were included in this analysis.
Data
Effectiveness
The number of organ donors and the observed and 
expected number of transplants for each OPO was obtained 
from OPO-specific reports from the SRTR (Supplementary 
material, A). The expected number of transplants for each 
organ is derived from a statistical model that adjusts for 
38 donor characteristics, such as age, cause of death, and 
medical co-morbidities, and is published by the SRTR (6) 
(see Table S1). The organ-specific observed-to-expected 
ratio (O:E) for each OPO represents the observed number 
of transplants for a given organ divided by the expected 
number of transplants for that organ. Local organ 
transplants were defined as those donated to a transplant 
center within the OPO’s donation service area (DSA), while 
export organ transplants were those donated outside of an 
OPO’s DSA (Figure 2). It is important to account for the 
local and export organ transplants in each OPO as the OAC 
for export organs is usually higher due to travel costs and 
greater logistical burden. January 1, 2013 to December 31, 
2014 was chosen as the study period, as this was the most 
recent period for which all required data were available.
Cost
The local and export organ-specific OACs for each OPO 
were obtained from OPO-reported data from the year 
2014 (presented at the Association of Organ Procurement 
Organizations annual meeting). The OPO-specific OACs 
have not been reported publicly since 2014.
Figure 1 Illustration of the specialized donor care facility (SDCF) model of donor care. In the conventional model of hospital-based donor 
care, a referring hospital notifies an organ procurement organization (OPO) of a potential organ donor, and the OPO then coordinates 
donor care and workup between the referring hospital, OPO, and transplant centers. In the SDCF model, the OPO transports brain 
dead donors to the SDCF for workup, medical optimization, recipient matching, and coordination of procurement, thereby streamlining 
donor care.
Brain dead potential multiorgan 
donor
Multiorgan procurement 
operation
SDCF model
• Donor transported to SDCF
• Donor directed care to optimize 
organ yield
Conventional model
• Donor care at hospital where brain 
death occurs
• No transportation required
• Managed by donor hospital ICU 
team with OPO staff assisting
Procuring surgical teams travel to 
SDCF
Procuring surgical teams travel to 
hospital
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Observed organ transplants 
For each OPO, the number of organ-specific observed 
transplants were obtained from the SRTR reports (6). 
Organ-specific observed total transplants nationwide were 
obtained by summing observed transplants from each OPO 
(Supplementary material, B). 
Observed costs 
For each OPO, organ-specific local and export OACs were 
used to compute the organ-specific observed average OAC 
(a weighted average of local and export OACs with weights 
determined by the number of local and export organs), 
and observed total costs (sum of local and export costs) 
(Supplementary material, C).
As an example, during the study period OPO A 
(conventional model) observed 307 liver transplants, 
including 203 local transplants with liver OAC = $30,000 
and 104 export transplants with liver OAC = $36,000. 
Thus, the liver-specific observed total costs for OPO A = 
($30,000×203) + ($36,000×104) = $9,834,000.
We then computed organ-specific observed average 
OAC nationwide by averaging observed organ-specific 
OACs from each OPO. Organ-specific observed total costs 
nationwide were derived from the sum of observed organ-
specific total costs from each OPO.
Predicted transplants assuming nationwide adoption of the 
SDCF model
We assumed a scenario in which all OPOs in the U.S. 
adopted the SDCF model and achieved the same 
effectiveness. Data from MOMA’s performance was used 
to inform effectiveness, as this was the nation’s only fully 
functioning SDCF in the year prior to the study period. 
Under such a scenario, we assume that each OPO has the 
same O:E as that of the SDCF while retaining its own 
capacity (E). Therefore, the organ-specific predicted total 
Figure 2 Illustration of local and export donations from two organ procurement organizations (OPOs). Each of the 58 OPOs in the U.S. 
manages a donation service area (DSA) (represented by black lines), which collectively encompass all 50 states. Using organ allocation 
algorithms and current policies, an OPO matches donor organs to recipients both inside its DSA, termed “local” transplants (blue lines), 
and outside its service area, termed “export” transplants (red lines). Export donations generally confer a higher OAC due to increased 
administrative burden and travel costs. These DSA boundaries are for illustrative purposes only and do not represent actual DSA boundaries.
Midwest donation 
service area
Northeast donation 
service area
Transplant 
center
OPO
Local
Export
Export
Transplant 
center
OPO
Local
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transplants was calculated by multiplying the organ-specific 
expected transplants for each OPO by the SDCF’s O:E 
ratio for that organ.
As an example, OPO A (conventional model) observed 
70 lung transplants from 367 donors during the study 
period, while 69.4 lung transplants were expected based on 
the SRTR’s statistical model (6). During the same period, 
the SDCF’s lung O:E was 1.18. Therefore, the predicted 
number of lung transplants from OPO A based on the 
SDCF’s performance =69.4×1.18=81.9. The organ-specific 
predicted total transplants nationwide were calculated by 
summing the predicted transplants for each OPO across all 
OPOs (Supplementary material, D). 
Predicted costs assuming nationwide adoption of the SDCF 
model
Under the aforementioned scenario in which all OPOs in 
the U.S. adopted the SDCF model, the observed OAC of 
the SDCF was assumed to be the organ-specific predicted 
average OAC for all OPOs (Supplementary material, E). 
The overall predicted average OAC was obtained by 
averaging the organ-specific predicted average OACs for 
the studied organs. 
As an example, during the study period OPO A 
(conventional model) was expected to perform 304 liver 
transplants with local and export proportions of 0.66 
and 0.34, respectively. The SDCF’s OAC for local liver 
transplants was $26,000, OAC for export liver transplants 
was $38,000, and O:E ratio of the SDCF model for liver 
was 1.06. As described above, the predicted number of 
liver transplants for OPO A =304×1.06=322. Thus, the 
liver-specific predicted total costs from OPO A =322 × 
($26,000×0.66 + $38,000×0.34) = $9,685,760. 
Statistical and economic analysis
The primary measure of benefit was the difference in total 
transplants and cost between the observed and predicted 
scenarios. The secondary measure of benefit was the 
difference in organ-specific transplants and cost between 
the two scenarios. All OPOs lacking complete cost or 
effectiveness data during the study period were excluded 
from the analysis. Descriptive statistics were computed. 
Bootstraps were performed to resample OPOs 1,000 times 
with replacement when computing the predicted transplants 
and costs to obtain means and 95% confidence intervals 
(CIs). Cost-effectiveness plane was plotted to demonstrate 
effectiveness (mean overall predicted total transplants 
from the bootstraps and overall observed total transplants) 
against cost (mean overall predicted total cost from the 
bootstraps and overall observed total cost). All analyses were 
conducted using Microsoft Excel, version 16 (Albuquerque, 
NM, USA).
Results
Nationwide observed cost and effectiveness
During the study period MOMA was the only established 
SDCF in the country which was transferring nearly all of 
its donors to the freestanding facility. Thirteen OPOs did 
not have complete data available and were excluded from 
the analysis (Figure S1). Nationwide, 38,944 transplants 
of the 5 organs of interest (heart, kidney, liver, lung, and 
pancreas) were observed from 13,539 individual donors (289 
transplants per 100 donors) over the 2-year study period 
(Table 1).
The nationwide observed total costs paid by transplant 
centers to the OPOs was $1.36 billion (Table 2). The 
observed average OAC was $37,599 per organ. Lungs had 
the highest observed average OAC ($46,276), followed by 
heart ($37,743).
Nationwide predicted costs and effectiveness presuming 
SDCF model of care
Assuming nationwide adoption of the SDCF model, the 
overall predicted total transplants nationwide would have 
been 39,155 (95% CI: 38,977–39,334), an increase of 211 
transplants compared to the observed effectiveness (Table 1). 
The overall predicted total organ cost nationwide was $1.26 
billion (95% CI: $1.26–1.27 billion), a decrease of $100 
million compared to the overall observed total organ costs 
nationwide. The predicted average OAC for every organ 
was lower compared to the observed average OAC based on 
the conventional model of care (overall mean $32,127 vs. 
$37,599) (Table 2).
Evaluation of the cost and effectiveness of nationwide 
adoption of the SDCF model
We evaluated the cost and effectiveness of nationwide 
adoption of the SDCF model by comparing the overall 
total transplants and organ costs between the observed and 
predicted scenarios. The predicted scenario dominated 
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the observed scenario by being less costly (i.e., nationwide 
predicted total costs − observed total costs = −$100 million; 
last column in Table 2) and more effective (i.e., nationwide 
predicted transplants − observed transplants = +211 
transplants; last column in Table 1) (Figure 3A).
Among the 211 additional transplants that were predicted 
with adoption of the SDCF model, 156 (74%) of these were 
from thoracic organs (heart and lungs). Subgroup analysis 
of thoracic organs alone demonstrated that the predicted 
scenario dominated the observed scenario by leading to an 
increase in thoracic transplants (+156) at a lower total organ 
cost (−$24.6 million) (Figure 3B). 
Discussion
We have performed an economic evaluation comparing 
the SDCF model of donor care to the conventional model 
of hospital-based care in the U.S. while accounting for 
regional variations in donor characteristics and patterns 
of organ sharing across the country’s OPOs. Our results 
show that the SDCF model may be a cost-effective means 
of donor management in the U.S. from a transplant 
center’s perspective, which may lead to an increase in 
thoracic organ transplants at a lower per transplant cost. 
While the predicted total number of organ transplants 
was slightly higher than the observed number of organ 
transplants, the predominant reason for the SDCF model’s 
cost-effectiveness is a substantially lowered predicted 
organ cost. With the changing landscape of organ donor 
management and the consistent increase in organ donors 
in recent years (7), these findings have important and far-
reaching implications for health care economics and donor 
management policy (8), both at a national and international 
level.
Table 1 Observed and predicted effectiveness of organ transplantation
Number of transplants HR KI LI LU PA Overall
Observed total transplants 
nationwide 
4,208 19,982 10,167 2,937 1,650 38,944
Observed transplants per  
100 donors nationwide 
31 149 76 21 12 289
Predicted total transplants 
nationwide (95% CI)
3,914  
(3,895, 3,932)
19,530  
(19,444, 19,615)
10,670  
(10,621, 10,719)
3,387  
(3,369, 3,404)
1,656  
(1,648, 1,663)
39,155  
(38,977, 39,334)
Predicted transplants per  
100 donors nationwide [95% CI]
29 [29, 29] 145 [145, 145] 79 [79, 79] 25 [25, 25] 13 [12, 13] 290 [290, 290]
Observed transplants refers to the actual number of organ transplants in total and per 100 donors during the study period. Predicted 
transplants refers to the number of organ transplants in total and per 100 donors based on the SDCF model and includes 95% confidence 
intervals (CIs). 95% confidence intervals were generated by the bootstrapped results. HR, heart; KI, kidney; LI, liver; LU, lung; PA, 
pancreas; AVG, national average; SDCF, specialized donor care facility. 
Table 2 Observed and predicted cost of organ transplantation
Cost HR KI LI LU PA Overall
Observed total cost ($) 156,882,745 646,509,241 366,444,371 132,045,589 59,229,109 1,361,111,055 
Predicted total cost  
(95% CI) ($)
126,630,733 
(126,031,400, 
127,230,066)
622,847,899 
(620,086,201, 
625,609,598)
320,790,524 
(319,346,831, 
322,234,218)
137,715,189 
(137,040,238, 
138,390,140)
53,464,409 
(53,219,362, 
53,709,456)
1,261,448,754 
(1,255,724,031, 
1,267,173,477)
Observed average OAC ($) 37,743 32,053 36,299 46,276 35,622 37,599 
Predicted average OAC ($) 30,407 32,000 28,862 36,576 32,792 32,127
Observed total cost and OAC refer to the actual total cost and average OAC during the study period. Predicted total cost and OAC refer 
to the total cost, including 95% confidence intervals (CIs), and average OAC based on the SDCF model. OACs are given as the weighted 
national average. 95% confidence intervals were generated by the bootstrapped results. All costs are in 2014 U.S. dollars. HR, heart; KI, 
kidney; LI, liver; LU, lung; PA, pancreas; OAC, organ acquisition charge; SDCF, specialized donor care facility. 
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The reasons for cost savings using the SDCF model 
are multifactorial but largely appear to be a result of lower 
overhead costs and greater efficiency in donor management. 
In the conventional model of donor care, all procedures 
and hospital-based workup add to the overall cost of donor 
management, which is paid for by the donor’s OPO. For 
example, if a donor needs a CT scan and bronchoscopy 
while at the referring hospital, both studies will confer 
additional cost to the OPO, which will ultimately be passed 
on to transplant centers through the OAC. Conversely, 
in the SDCF model the diagnostic workup is centralized, 
with radiographic studies, diagnostic testing, and laboratory 
analysis being performed at the SDCF via OPO-owned 
resources. Similarly, the SDCF model is likely to result 
in lower professional fees as well. A donor requiring 
bronchoscopy and dialysis in the conventional setting 
will be managed by a pulmonologist and a nephrologist, 
while in the SDCF model, a critical care physician or 
other personnel, who are extremely familiar with donor 
management and employed by the OPO, will provide 
these services. Donor care is a complex process that most 
hospitals are unfamiliar with. In this regard, the SDCF can 
be regarded as a “high-volume” center that performs these 
complex tasks frequently and efficiently. By co-locating 
services, such as radiographic machines, diagnostic testing 
equipment, intensive care units, and procurement operating 
rooms, the SDCF is able to simplify the donor management 
process. Despite recent changes in organ allocation policy 
in the U.S., the benefits of the SDCF are likely to be 
maintained due to inherent efficiencies of the model that 
facilitates a streamlined organ donor management and 
recovery process and lowers the cost of donor care.
The SDCF model can reliably institute specific 
algorithms to increase organ yield, which may be one factor 
contributing to the increase in effectiveness. A prior study 
by our group demonstrated that a lung focused resuscitation 
protocol implemented by a SDCF led to increased organ 
yield (5). Similarly, a previous study from our institution 
demonstrated that transferring a donor to a SDCF 
increased the overall organ yield (3.43 vs. 2.69 organs per 
donor, P<0.0001) and was associated with a lower mean 
donor recovery cost ($16,153 vs. $33,161, P<0.0001) (4). 
The transfer process itself appears to be relatively quick, 
with a median time from family consent to transfer of 
8.6 hours, and has been associated with a very high family 
satisfaction (4). We have also found that procurement from 
the SDCF, rather than a referring hospital, was correlated 
with higher likelihood of daytime, rather than after-hours 
transplants (9). Therefore, it appears that transfer to a 
SDCF is efficient from a number of perspectives, including 
that of surgeons and donor families, and may confer other 
advantages not examined in this study. It remains to be 
seen if the benefits of a SDCF appreciated in the U.S. will 
be seen in other countries. To our knowledge no similar 
facilities exist outside of the U.S. However, we strongly 
anticipate that the fundamental efficacy of the SDCF model 
Figure 3 Observed and predicted overall cost and effectiveness of the specialized donor care facility (SDCF) model of care compared to the 
conventional model. Overall total costs nationwide are shown in billions and millions of U.S. dollars for all organs (A) and thoracic organs 
(B), respectively. Overall total transplants nationwide refer to the sum of all transplants done by the 45 organ procurement organizations 
(OPOs) in this study for the 5 organs of interest (heart, liver, lung, kidney, pancreas). Thoracic organs represent the sum of lung and heart 
transplants alone. The observed data point is based on the actual outcomes during the study period, while the predicted data point is based 
on nationwide adoption of the SDCF model during the study period.
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can be replicated not only in the U.S., but internationally.
Since the SDCF model requires a freestanding organ 
recovery center, the cost of initiating this model is worthy 
of discussion. A prior study of our local SDCF estimated 
the startup cost to be $5.34 million (construction, medical 
equipment, etc.) (4). In the current study we found a cost 
savings of $100 million for 45 OPOs using the SDCF 
model, resulting in approximately $2.2 million in savings 
per OPO during the study period. Therefore, one could 
envision that OPOs could use the differences in cost of 
donor management to offset startup costs. Our results also 
suggest that implementation of the SDCF model may be in 
the best interest of transplant centers as well, and they may 
be incentivized to fund a portion of a SDCF’s startup cost.
A few critical elements are required for the SDCF 
model to succeed and these should be carefully considered 
before another country or other U.S. OPOs adopt this 
model. First, the donor volume should be high enough that 
the cumulative OACs can finance the costs of running a 
SDCF. The leadership at our local OPO has estimated this 
number to be around 100 donors per year, which would 
have encompassed 38 of the 58 OPOs during our study 
period. It appears that the SDCF model functions optimally 
when built geographically close to high volume transplant 
centers, as this has been shown to reduce travel time and 
the number of “fly outs” by the procurement team in both 
real (3) and hypothetical (10) models of donor management. 
In the setting of new U.S. organ allocation policies, which 
have been shown to increase air travel (8), it may be ideal to 
locate new SDCFs close to airports.
Our results must be interpreted with some limitations 
in mind. We have conducted an economic evaluation 
from the perspective of U.S. transplant centers, which 
is only one of several perspectives that one could take 
when conducting such an analysis. The perspective of the 
payer (i.e., private insurance companies or the Center for 
Medicare & Medicaid Services), the referring hospital, and 
donor families was not examined in this analysis. The study 
period represents the most recent era for which all required 
U.S. cost data were available, and costs may have changed 
since then. Notably, while all 58 OPOs in the country 
are not for profit organizations, various OPOs are likely 
to have different margins of “profit” for different organs; 
unfortunately, this information is unavailable and unlikely 
to become available in the public domain. Hence, we used 
publicly available OACs as our best proxy of true cost of 
organs.
Given that transferring a donor to a SDCF generates 
an additional cost to the OPO, which will ultimately be 
passed on to transplant centers through the OAC, the 
geographic location of a SDCF may influence overhead 
cost. Furthermore, one limitation of this study is that 
our use of the O:E ratio as a measure of performance is 
nuanced and potentially reflective of the performance 
of accepting transplant centers in close proximity to the 
OPO. For example, our local OPO (MOMA) transfers 
31% of donors to the SDCF by plane and the remainder 
by ground, which may not be representative of other 
OPOs (4); this is particularly relevant for countries that 
share organs across international lines, a model adopted in 
Europe (11). Furthermore, given that no other OPOs had 
fully implemented a SDCF during the study period, our 
results are extrapolated from the performance of a single 
SDCF, which may have overstated or understated certain 
aspects of cost or effectiveness. However, with four other 
OPOs having adopted the SDCF model since 2014 and 
seven others in the process of doing so, it appears that the 
U.S. healthcare system is already aligning itself with the 
most cost-effective model of donor care. As more SDCFs 
are implemented across the country and their data becomes 
available, studies will be undertaken which examine the 
performance of multiple centers using this model.
In conclusion, we have found that from a U.S. transplant 
center’s perspective the SDCF is a less costly, more 
effective model of donor care, particularly with regard 
to thoracic organs, when compared to the conventional 
model of hospital-based donor care. Our study predicts 
that nationwide adoption of the SDCF would result 
in a slightly higher number of organ transplants while 
substantially lowering the cost of organ acquisition. We 
urge international policymakers, payers, and transplant 
centers to consider incentives that facilitate a transition to 
the SDCF model of donor care.
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Supplementary
Abbreviations
	y: organ of interest (heart, liver, lung, kidney, or pancreas);
	OBS: observed;
	EXP: expected;
	PRED: predicted;
	Σ: total;
	x: average;
	TXP: transplants;
	TXP/100: transplants per 100 donors.
A. Data
The following data were obtained from the SRTR reports (5): organ-specific observed transplants (yOBS TXP), number of 
organ donors, local and export number of transplants (yTXPlocal, yTXPexport), and organ-specific observed-to-expected ratios 
(O:E) for each OPO. The local and export organ-specific OACs for each OPO was obtained from OPO-reported data from 
the year 2014.
B. Observed organ transplants
Organ-specific observed total transplants nationwide (yOBS Σ TXP nationwide) was obtained by summing yOBS ΣTXP for 
OPOi, i=1,...,n over all OPOs. 
1
n
i
i
yOBS TXP nationwide yOBS TXP for OPO
=
∑ =∑  [1]
where i is the index for OPO, and n is the number of all OPOs.
Overall observed total transplants nationwide was computed by summing yOBS ΣTXP nationwide over all interested 
organs:
   
    
  
y
y
yOBS TXP nationwide
overall OBS TXP nationwide
∑
∑ =
∑
∑
 [2]
where y is organ of interest: heart, liver, lung, kidney, or pancreas.
The organ-specific observed transplants per 100 donors for OPOi is obtained by 
    /100 100.
     
i
i
i
yOBS TXP for OPOyOBS TXP for OPO
number of organdonors for OPO
= ×  [3]
 
Organ-specific observed total transplants nationwide per 100 donors is computed as follows:
1
 /100 ? /100
n
i
i
yOBS TXP nationwide yOBS TXP for OPO
=
=∑  [4]
Overall observed total transplants nationwide per 100 donors was computed by summing yOBS ΣTXP/100 nationwide over 
all interested organs:
  /100
   /100
  
y
y
yOBS TXP nationwide
overall OBS TXP nationwide
∑
∑ =
∑
∑
 [5]
C. Observed costs
Organ-specific OAC for OPOi was obtained by the weighted average of local yOAC and export yOAC, where weights were 
determined by the number of local transplants and the number of export transplants:
[6]    OAC OAC    
local export
local exporti i
i i ilocal export local export
i i i i
yTXP yTXPyOAC for OPO y y
yTXP yTXP yTXP yTXP
= × + ×
+ +
 
Organ-specific observed average OAC was computed by:
1 
n
ii
yOAC
yOBS x OAC
n
== ∑  [7]
Overall observed average OAC was computed by:
  
  
y
y
yOBS x OAC
overall OBS x OAC =
∑
∑
 [8]
Organ-specific observed cost (yOBS Σcost) for each OPO was computed by multiplying the local OAC (yOAClocal) by 
the number of local y transplants and adding this to the product of export OAC (yOACExport) and the number of export y 
transplants. 
     OAC OAClocal local export exporti i i i iyOBS costs for OPO y yTXP y yTXP= × + ×  [9]
Organ-specific observed total costs nationwide were then obtained by
1
      
n
i
i
yOBS costs nationwide yOBS costs for OPO
=
∑ =∑  [10]
Overall observed total costs nationwide were obtained by summing organ-specific observed total costs nationwide over all 
interested organs, as follows:
       
y
overall OBS costs nationwide yOBS costs nationwide∑ = ∑∑  [11]
D. Predicted organ transplants assuming nationwide adoption of the SDCF model
Assuming nationwide adoption of the SDCF model, SDCF
Oy
E
 
 
   will be used as the effectiveness of each OPO, while organ-
specific expected total transplants for each OPO remains the same. The organ-specific predicted transplants (yPRED ΣTXP) 
for each OPO was calculated by multiplying the organ-specific expected total transplants (yEXP ΣTXP) for each OPO by the 
SDCF’s O:E ratio for that organ [
SDCF
Oy
E
 
 
 
]. 
      i i
SDCF
OyPREDTXP for OPO yEXPTXP for OPO y
E
 = ×  
 
 [12]
Organ-specific predicted total transplants nationwide (yPRED ΣTXP nationwide) was computed by summing yPRED 
ΣTXP for each OPO over all OPOs. 
1
      
n
i
i
yPRED TXP nationwide yPRED TXP for OPO
=
∑ =∑  [13]
Overall predicted total transplants nationwide was calculated by summing yPRED ΣTXP nationwide over all interested 
organs, as follows:
       
y
overall PRED TXP nationwide yPRED TXP nationwide∑ = ∑∑  [14]
Organ-specific predicted transplants per 100 donors for each OPO was obtained by
    /100 100
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yPREDTXP for OPOyPREDTXP for OPO
number of organdonors for OPO
= ×  [15]
The organ-specific predicted total transplants nationwide per 100 donors (yPRED TXP/100 nationwide) was computed 
by. 
1
  /100 /100
n
i
i
yPRED TXP nationwide yPRED TXP for OPO
=
∑ =∑  [16]
Overall predicted total transplants nationwide per 100 donors was calculated by summing yPRED TXP/100 nationwide 
over all interested organs, as follows:
   /100 /100
y
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y
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E. Predicted costs assuming nationwide adoption of the SDCF model
Organ-specific predicted average OAC was computed by:
1
    
 
n
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yPREDOAC for OPO
yPRED x OAC
n
==∑  [18]
where
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SDCF SDCF SDCF SDCF
yTXP yTXPyPREDOAC for OPO y y
yTXP yTXP yTXP yTXP
= × + ×
+ +
 
[19]
Therefore,  SDCFyPRED x OAC yPRED x OAC= .
Overall predicted average OAC for each OPO was computed by taking the average of yPRED x OAC over all interested 
organs.
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Organ-specific predicted costs for each OPO were obtained by:
         i i iyPREDcosts for OPO yPREDTXP for OPO yPREDOAC for OPO= ×
 [21]
Organ-specific predicted total costs nationwide were then computed by:
1
      
n
i
i
yPRED costs nationwide yPRED costs for OPO
=
∑ =∑  [22]
Figure S1 Flow diagram of OPOs and transplants included in the study. Of the 58 OPOs in the U.S., 45 had complete cost and effectiveness 
data for the 2-year study period. Due to their rarity, small bowel transplants were excluded from the study. Single and double lung 
transplants are counted as one organ, while kidney transplants are counted separately. Data taken from SRTR reports (5). OPOs, organ 
procurement organizations; SRTR, Scientific Registry of Transplant Recipients.
Table S1 Predictors of organ yield
Age effect for brain dead donors
Blood type
Body mass index
Cardiac arrest after brain death
Cause of death
Circumstance of death
Clinical infection: blood
Clinical infection: lung
Clinical infection: other
Clinical infection: urine
Controlled DCD donor
Current cigarette use
Current cocaine use
Current other drug use
Ejection fraction (percent)
Ethnicity
Gender
Heavy alcohol use
Height 
History of cancer
History of cocaine use
History of diabetes
History of hypertension
History of insulin dependence
History of other drug use
Intercept
Mechanism of death
More than 20 pack years
PHS increased infectious risk
pO2/FiO2 ratio
pO2
Previous MI
Protein in urine
Race
Terminal serum creatinine
Weight
History of any diabetes
Recovered outside the contiguous 48 states?
Donor characteristics used by the Scientific Registry of 
Transplant Recipients to determine expected organ yield for 
each OPO based on the number of potential organ donors. 
OPO, organ procurement organization; DCD, donation after 
cardiac death; PHS, U.S. Public Health Service.
